Govx stock forecast the latest "govx stock forecast"

The latest "govx stock forecast" shows short-term volatility, with shares trading around $0.75, down 3% intraday. Analysts expect a potential rebound if biotech sector momentum recovers, especially given upcoming FDA data announcements. Terms and Privacy Policy Your Privacy Choices CA Privacy Notice More Info GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats. Analysts project the "govx stock forecast" could test $1.00 in the medium term if trial data is favorable and biotech indexes rally.